New Data Presented at 64th AAN Annual Meeting Highlights Biogen Idec's …MarketWatch (press release)… and FAMPYRA(R) (prolonged-release fampridine tablets) — the company will present results from investigational trials of its late-stage pipelin…
Abbott Laboratories Management Discusses Q1 2012 Results – Earnings Call …Seeking AlphaDaclizumab is a next-generation biologic in development for MS. Last year, Abbott and our partner company announced promising results from the first of 2 registrat…
Abbott Beats, Raises Outlook – Analyst BlogNASDAQAbbott Labs, along with partner Biogen ( BIIB ), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis ( RRMS ). Abbott Labs is also working on an inte…
Dividend.comAbbott Beats, Raises OutlookZacks.comAbbott Labs, along with partner Biogen (BIIB), is evaluating daclizumab in a phase III study for the treatment of relapsing-remitting multiple sclerosis (RRMS). Abbott Labs is also working on an intestin…
Medill Reports: ChicagoAbbott Reports Double-Digit Ongoing Earnings-Per-Share Growth in First Quarter …MarketWatch (press release)Abbott's partnership with Biogen Idec includes development of a novel, next-generation antibody, daclizumab, which i…
Pharmazeutische Zeitung onlineBelatacept: Nutzenbewertung des IQWiG liegt vorPharmazeutische Zeitung onlineBeide Gruppen erhielten zusätzlich Corticosteroide, Mycophenolat und zu Therapiebeginn zudem den Antikörper Basiliximab. In Bezug auf Sterblich…
Biogen's Fampyra Launched in Canada – Analyst BlogNASDAQBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs ( ABT ), and PEGylated interferon. Biogen recently signed an exclusive,…
Biogen's Fampyra Launched In CanadaDaily MarketsBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (NYSE:ABT), and PEGylated interferon. Biogen recently signed an exclusive, worl…
Biogen's Fampyra Launched in CanadaZacks.comBesides BG-12, Biogen is developing other multiple sclerosis candidates like daclizumab, in partnership with Abbott Labs (ABT), and PEGylated interferon. Biogen recently signed an exclusive, worldwide opt…
Transplantation bei Kindern: Blutgruppen-Inkompatibilität lässt sich überwindenPabst Science Publishers… parallel entfernte eine mehrfache Immunabsorption die (für Abstoßungen mitverantwortlichen) Isoagglutinine; und gleichzeitig wurde eine vier…